<DOC>
	<DOCNO>NCT00060372</DOCNO>
	<brief_summary>This phase I trial study well ipilimumab work allogeneic stem cell transplant treat patient persistent progressive cancer . Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell .</brief_summary>
	<brief_title>Ipilimumab After Allogeneic Stem Cell Transplant Treating Patients With Persistent Progressive Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose MDX-010 ( ipilimumab ) safely administer patient persistent progressive malignancy follow allo-HCT . II . To determine pharmacokinetics different dos MDX-010 administer single dose patient persistent progressive malignancy follow allo-HCT . III . By assessment aim 1 2 , determine best dose regimen study CTLA-4 blockade conjunction escalate dose donor-leukocyte infusion ( DLI ) patient evidence residual progressive malignancy follow allo-HCT . IV . To assess preliminary evidence efficacy follow administration MDX-010 population . OUTLINE : Patients receive ipilimumab intravenously ( IV ) 90 minute . Cohorts 3-6 patient receive escalate dos ipilimumab maximum tolerate dose ( MTD ) determine . The MTD dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients persistent progressive disease 60 day ipilimumab administration evidence graft-versus-host disease receive donor lymphocyte infusion every 60 day total 3 infusion . Patients follow 4 , 5 , 6 , 9 , 12 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Embryonal</mesh_term>
	<mesh_term>Endodermal Sinus Tumor</mesh_term>
	<mesh_term>Seminoma</mesh_term>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Dermoid Cyst</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis persistent progressive hematologic malignancy solid tumor allogeneic hematopoietic stem cell transplantation ( AHSCT ) Patients eligible study entry time posttransplantation day 90 3 year withdrawal immunosuppressive therapy Acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) meet follow criterion : hematologic relapse standard criterion , hematologic persistence evidence bone marrow blast &gt; 10 % day 30 postAHSCT Cytogenetic progression evidence increase percentage Philadelphia chromosome ( Ph ) 1positive metaphase ( Ph1positive cell fluorescent situ hybridization ) complete cytogenetic response ( 0 % Ph1positive cell ) partial response ( 134 % Ph1positive cell ) ; PR minor response ( 3594 % Ph1positive cell ) ; MR response ( 95100 % Ph1positive cell ) Resistance imatinib mesylate , define disease progression ( hematologic , cytogenetic , molecular ) OR failure respond ( i.e. , lack complete hematologic response 3 month , lack partial cytogenetic response 6 month , lack complete cytogenetic response 12 month ) prior imatinib mesylate therapy Myelodysplastic syndromes meet following criterion : Hematologic relapse standard criterion , cytogenetic relapse evidence recurrence clonal abnormality patient achieve CCR AHSCT , hematologic persistence evidence cytopenia attributable posttransplant cause accompany characteristic morphological change 90 day AHSCT OR ; Hematologic persistence evidence cytopenia attributable posttransplant cause accompany characteristic morphological change 90 day AHSCT , cytogenetic persistence evidence persistence clonal abnormality 90 day AHSCT Chronic lymphocytic leukemia meet follow criterion : great 25 % increase absolute lymphocytosis &gt; 5,000/mm3 , great 25 % increase measurable lymphadenopathy , persistence absolute lymphocytosis &gt; 5,000/mm3 day 90 later AHSCT , persistence lymphadenopathy ≥ 3 cm diameter day 90 later AHSCT Aggressive nonHodgkin 's lymphoma ( e.g. , diffuse large cell lymphoma , lymphoblastic lymphoma , mantle cell lymphoma , peripheral T cell lymphoma ) , Hodgkin 's lymphoma , OR solid tumor meet follow criterion : great 50 % increase measurable evaluable disease , persistence measurable lesion &gt; 3.0 cm diameter day 90 later AHSCT OR ; Persistence malignancy biopsy positron emission tomography scan unless clear evidence progression Multiple myeloma demonstrate resistance intolerance prior thalidomide bortezomib unless agent contraindicate ( e.g. , due peripheral neuropathy ) meeting follow criterion : great 25 % increase paraprotein band , abnormal quantitative immunoglobulin level , urine protein excretion OR Greater 25 % increase percent plasma cell bone marrow ( &gt; 15 % ) , presence new lytic bone lesion , new extramedullary lesion OR ≥ 25 % enlargement exist extramedullary lesion , persistence paraprotein band , abnormally elevate quantitative immunoglobulin level , bone marrow plasmacytosis &gt; 15 % period least 90 day AHSCT At least 1 bidimensionally measurable lesion ≥ 1.5 cm diameter Evaluable disease define disease assessable response ( e.g. , pleural effusion , elevate serum tumor ) Bone metastasis assess CT scan MRI consider evaluable Leukemia consider evaluable disease Patients meet criterion persistence progression AML , ALL , CML , aggressive NHL AND currently complete remission reinduction therapy require measurable evaluable disease eligible At least 50 % donor chimerism Tcell lineage OR full ( ≥ 90 % ) donor chimerism unseparated blood last assessment within 3 month study entry No evidence consecutive test &gt; 10 % decline Tcell chimerism beyond error test ECOG 02 Life expectancy : More 3 month No prior grade 3 4 acute graftvshost disease No concurrent autoimmune diseases require chronic use immunosuppressive medication , active connective tissue disease , CNS disease include multiple sclerosis demyelinate disease , inflammatory bowel disease , autoimmune hepatitis No ongoing serious infection Negative pregnancy test Fertile patient must use effective contraception least 4 month study therapy No serious ongoing medical condition would preclude study participation No malignancy within past 5 year No psychological psychiatric condition would preclude study participation No prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody ( MDX010 ) At least 6 week since prior immunosuppressive agent At least 2 week since prior imatinib mesylate No concurrent imatinib mesylate At least 6 week since prior concurrent immunosuppressive agent clinically active graftversushost disease ( GVHD ) prophylaxis treatment No concurrent investigational agent OR Cytogenetic persistence evidence Ph1positive metaphase bone marrow day 90 postAHSCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>